Summary
Cancer is the 2nd most common cause of death worldwide. Oncological surgery is the most efficient single-treatment and is the most used as primary treatment. However, the local cancer recurrence rate after the first surgery is still high in every organ. Local cancer recurrence is mainly caused by tumor growth from remaining tumor residues. They have a major impact on survival, quality of life and require reinterventions and/or adjuvant treatments. Therefore, the main issue today in oncological surgery today is to ensure the resection quality and remove the whole tumor while minimizing healthy tissues removal. To achieve it, surgeons need real time information on tumor residues’ location.
Beams is a medtech company, incorporated on the 17th of May 2021 to answer this unmet medical need. Beams develops TRIOP (Tumor Resection IntraOperative Probe) technology, a miniaturized intraoperative probe which measures the accumulation of existing radiotracers in tumor tissues after their injection in the organism, and then informs surgeons in real time about the precise tumor localization to help removing the tumor while preserving surrounding healthy tissues. The targeted impact is to prevent local cancer recurrence and to preserve patients’ quality of life.
The first Beams’ product based on TRIOP technology will be a multi-purpose intelligent surgical aspirator: the detection system will be built around an aspiration tool, to remove tumor cells, blood and other secretions that could alter the detection simultaneously with examining the operative cavity.
Beams is a medtech company, incorporated on the 17th of May 2021 to answer this unmet medical need. Beams develops TRIOP (Tumor Resection IntraOperative Probe) technology, a miniaturized intraoperative probe which measures the accumulation of existing radiotracers in tumor tissues after their injection in the organism, and then informs surgeons in real time about the precise tumor localization to help removing the tumor while preserving surrounding healthy tissues. The targeted impact is to prevent local cancer recurrence and to preserve patients’ quality of life.
The first Beams’ product based on TRIOP technology will be a multi-purpose intelligent surgical aspirator: the detection system will be built around an aspiration tool, to remove tumor cells, blood and other secretions that could alter the detection simultaneously with examining the operative cavity.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101114157 |
| Start date: | 01-07-2023 |
| End date: | 31-03-2024 |
| Total budget - Public funding: | - 75 000,00 Euro |
Cordis data
Original description
Cancer is the 2nd most common cause of death worldwide. Oncological surgery is the most efficient single-treatment and is the most used as primary treatment. However, the local cancer recurrence rate after the first surgery is still high in every organ. Local cancer recurrence is mainly caused by tumor growth from remaining tumor residues. They have a major impact on survival, quality of life and require reinterventions and/or adjuvant treatments. Therefore, the main issue today in oncological surgery today is to ensure the resection quality and remove the whole tumor while minimizing healthy tissues removal. To achieve it, surgeons need real time information on tumor residues’ location.Beams is a medtech company, incorporated on the 17th of May 2021 to answer this unmet medical need. Beams develops TRIOP (Tumor Resection IntraOperative Probe) technology, a miniaturized intraoperative probe which measures the accumulation of existing radiotracers in tumor tissues after their injection in the organism, and then informs surgeons in real time about the precise tumor localization to help removing the tumor while preserving surrounding healthy tissues. The targeted impact is to prevent local cancer recurrence and to preserve patients’ quality of life.
The first Beams’ product based on TRIOP technology will be a multi-purpose intelligent surgical aspirator: the detection system will be built around an aspiration tool, to remove tumor cells, blood and other secretions that could alter the detection simultaneously with examining the operative cavity.
Status
SIGNEDCall topic
HORIZON-EIE-2022-SCALEUP-02-02Update Date
31-07-2023
Images
No images available.
Geographical location(s)
